Nature Reviews Cancer

Papers
(The H4-Index of Nature Reviews Cancer is 76. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Targeting ferroptosis as a vulnerability in cancer1014
Cancer metabolism: looking forward884
Therapeutic cancer vaccines827
Systemic immunity in cancer746
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion715
The role of ROS in tumour development and progression702
Connecting copper and cancer: from transition metal signalling to metalloplasia665
Endoplasmic reticulum stress signals in the tumour and its microenvironment638
The matrix in cancer549
The metabolism of cancer cells during metastasis526
Recent advances and discoveries in the mechanisms and functions of CAR T cells520
Interleukins in cancer: from biology to therapy404
Long noncoding RNAs in cancer metastasis398
Advances in bladder cancer biology and therapy372
Exploiting senescence for the treatment of cancer369
Natural killer cells in antitumour adoptive cell immunotherapy322
Linking EMT programmes to normal and neoplastic epithelial stem cells316
Advancing targeted protein degradation for cancer therapy304
Cancer stem cell–immune cell crosstalk in tumour progression303
Targeting DNA damage response pathways in cancer279
The immunological and metabolic landscape in primary and metastatic liver cancer279
Harnessing multimodal data integration to advance precision oncology232
Autophagy in tumour immunity and therapy227
The language of chromatin modification in human cancers220
CRISPR in cancer biology and therapy213
Targeting CDK4 and CDK6 in cancer209
Designing deep learning studies in cancer diagnostics205
Cancer nanomedicine194
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs194
Tumour fatty acid metabolism in the context of therapy resistance and obesity191
Targeting FAK in anticancer combination therapies187
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities184
Programmed death ligand 1 signals in cancer cells183
Genetic and non-genetic clonal diversity in cancer evolution181
MYC protein interactors in gene transcription and cancer176
Liquid–liquid phase separation drives cellular function and dysfunction in cancer173
A timeline of tumour-associated macrophage biology169
Targeting the DNA damage response in immuno-oncology: developments and opportunities168
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data165
Overcoming TGFβ-mediated immune evasion in cancer165
Antitumour immunity regulated by aberrant ERBB family signalling162
Sex disparities matter in cancer development and therapy159
Mutational signatures: emerging concepts, caveats and clinical applications155
Clonal expansion in non-cancer tissues150
Towards targeting of shared mechanisms of cancer metastasis and therapy resistance150
RNA splicing dysregulation and the hallmarks of cancer145
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer144
Stress and cancer: mechanisms, significance and future directions141
The plasticity of mRNA translation during cancer progression and therapy resistance135
Mitochondrial DNA variation and cancer132
Polyamines in cancer: integrating organismal metabolism and antitumour immunity130
Dynamics and specificities of T cells in cancer immunotherapy127
Aneuploidy as a promoter and suppressor of malignant growth127
Mechanisms of immune activation and regulation: lessons from melanoma120
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment118
mRNA-based cancer therapeutics117
Big data in basic and translational cancer research114
Artificial intelligence in cancer research, diagnosis and therapy109
Glial and myeloid heterogeneity in the brain tumour microenvironment108
Cancer proteogenomics: current impact and future prospects105
Biology, vulnerabilities and clinical applications of circulating tumour cells104
Advances in germline predisposition to acute leukaemias and myeloid neoplasms103
Synthetic biomarkers: a twenty-first century path to early cancer detection102
Nucleotide metabolism: a pan-cancer metabolic dependency101
Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies97
STAT proteins in cancer: orchestration of metabolism96
Smokeless tobacco and cigarette smoking: chemical mechanisms and cancer prevention96
Decoding leader cells in collective cancer invasion93
Therapeutic targeting of tumour myeloid cells92
Mapping the genomic diaspora of gastric cancer91
Targeting the gut microbiota for cancer therapy91
Leukaemia: a model metastatic disease90
The coming decade in precision oncology: six riddles88
Mechanisms driving the immunoregulatory function of cancer cells84
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment83
Acetyl-CoA metabolism in cancer76
0.034600973129272